Senelix
- Biotech or pharma, therapeutic R&D
Senelix (Senescence+Elixir) is a pre-clinical stage biotech developing therapies for aging & inflammatory diseases by targeting the core aging processes.
Senelix explores Cellular senescence and Immunosenescence. Senescent cells are the primary cause of aging and persistent inflammatory diseases, including atopic dermatitis, IBD, rheumatoid arthritis, IPF, systemic sclerosis, and Alzheimer’s. Senescence contributes to persistent inflammation and exacerbates pathology. Senescent cells must undergo apoptosis or be killed and removed by immunity.
Senelix found that a blood-circulating CHI3L1 is a target that regulates cellular and immunosenescence, and is developing anti-CHI3L1 mAb for a variety of aging and immune diseases (SL300).
Senelix has two preclinical candidates.
SL300: Anti-CHI3L1 mAb for inflammatory and fibrotic diseases
SL100: Ophthalmic solutions with new synthetic compound for dry eye and ocular pains.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}